Treatment of Angioedema Attacks in Pediatric (Ages 2-11) Post-Trial and Naive Patients With HAE With Sebetralstat

Study to Evaluate Ecallantide in Paediatric Patients With Acute Attacks of Hereditary Angioedema

NCT01253382 ·Status: WITHDRAWN ·Phase: PHASE2/PHASE3

Study to Assess the Tolerability and Safety of Ecallantide in Children and Adolescents With Hereditary Angioedema

NCT01832896 ·Status: WITHDRAWN ·Phase: PHASE2

Expanded Access for the Prevention of Acute Attacks of 1) Hereditary Angioedema (HAE) in Children and 2) Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH) in Teenagers and Adults

NCT04583007 ·Status: NO_LONGER_AVAILABLE

A Study of Navenibart (STAR-0215) in Participants With Hereditary Angioedema

NCT05695248 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

A Long-term Study of STAR-0215 in Participants With Hereditary Angioedema

NCT06007677 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema

NCT05819775 ·Status: COMPLETED ·Phase: PHASE3

A Study of Lanadelumab to Prevent Hereditary Angioedema (HAE) Attacks in Children

NCT04070326 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE

NCT03485911 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema

NCT02870972 ·Status: COMPLETED ·Phase: PHASE2

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

NCT07001280 ·Status: RECRUITING

C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks

NCT00289211 ·Status: COMPLETED ·Phase: PHASE3

A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks

NCT07009262 ·Status: COMPLETED

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

NCT05120830 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab

NCT06806657 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Oral Deucrictibant for Prophylactic and Acute Treatment in Hereditary Angioedema Patients

NCT07046806 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881 ·Status: RECRUITING ·Phase: PHASE3

A Long Term Safety Study of BCX7353 in Hereditary Angioedema

NCT03472040 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Donidalorsen Treatment in Children With Hereditary Angioedema

NCT07298447 ·Status: RECRUITING ·Phase: PHASE3

Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06669754 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema

NCT02316353 ·Status: COMPLETED ·Phase: PHASE3

A Phase 2 HAE Prophylaxis Study With Recombinant Human C1 Inhibitor

NCT02247739 ·Status: COMPLETED ·Phase: PHASE2

Study of Ravulizumab in Pediatric Participants With Primary IgAN

NCT07024563 ·Status: RECRUITING ·Phase: PHASE3

Efficacy, Safety and Tolerability of Icatibant for the Treatment of HAE

NCT01457430 ·Status: COMPLETED ·Phase: PHASE4

A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema

NCT01386658 ·Status: COMPLETED ·Phase: PHASE3

C1-INH Compared to Placebo at the Time of Prodromal Symptoms for Hereditary Angioedema (HAE) Exacerbation

NCT01151735 ·Status: WITHDRAWN ·Phase: PHASE4